<DOC>
	<DOCNO>NCT01701973</DOCNO>
	<brief_summary>This study test follow hypothesis : Aim 1 : Test hypothesis acute dipeptidyl peptidase 4 ( DPP4 ) inhibition currently available anti-diabetic drug , sitagliptin , increase stimulate growth hormone ( GH ) secretion healthy lean adult decrease degradation growth hormone release hormone ( GHRH ) . Aim 2 : Test hypothesis decrease degradation GHRH acute DPP4 inhibition result increase endothelium-dependent vasodilation mediate GH independent GLP-1 healthy lean adult . This study promise provide novel data regard increasingly use class anti-diabetic drug affect pituitary GH axis could affect blood vessel relaxation . Growth hormone level low set obesity pre-diabetes . A study may evaluate effect chronic DPP4 inhibitor therapy population patient obesity pre-diabetes .</brief_summary>
	<brief_title>Effect DPP4 Inhibition Growth Hormone Secretion</brief_title>
	<detailed_description>Growth hormone secretion low patient obesity , insulin resistance , hyperlipidemia . GH therapy population others limited side effect include hyperglycemia . Another strategy increase GH secretion enhance pulsatile GH secretion growth hormone release hormone . Growth hormone release hormone ( GHRH ) half life 5 minute due rapid inactivation DPP4 . An alternative strategy increase endogenous GH secretion inhibit degradation GHRH DPP4 . DPP4 inhibitor currently approve therapy treatment hyperglycemia patient type 2 diabetes mellitus . They additionally cause blood vessel relaxation . We therefore propose test hypothesis DPP4 inhibition simultaneously enhance GH secretion improve blood glucose vascular function patient population low GH increase cardiovascular risk . These preliminary aim serve primarily novel `` proof concept '' study define effect acute pharmacologic DPPIV inhibition stimulate GH secretion .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>omega-N-Methylarginine</mesh_term>
	<criteria>Age 18 40 year inclusive BMI ≤ 25 kg/m2 For female subject : Statuspost surgical sterilization , If childbearing potential , utilization barrier method birth control follow negative serum βHCG screen visit every study day Smoking Type 1 Type 2 Diabetes Mellitus , define fast glucose 126 mg/dL great time screen visit use antidiabetic medication Hypertension , define untreated seated SBP great 140 mmHg and/or untreated DBP great 90 mmHg time screen visit use antihypertensive medication History report record hypoglycemia ( plasma glucose &lt; 70 mg/dL ) Pregnancy and/or BreastFeeding Use medication multivitamin , include use transdermal well oral hormone replacement therapy use oral contraceptive therapy Anemia define hematocrit &lt; 35 % screen visit Cardiovascular cerebrovascular disease , include history myocardial infarction , history congestive heart failure , history stroke Pulmonary Hypertension Abnormal thyroid hormone level ( TSH ) time screen visit Abnormal serum IGF1 time screen visit Impaired renal function , define eGFR &lt; 60 mL/min/1.73M2 Impaired hepatic function ( AST ALT &gt; 2 X upper limit normal range ) Treatment investigational drug 1 month preceding study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>obesity</keyword>
	<keyword>growth hormone</keyword>
</DOC>